



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Matthew C. Coffey

Application No.: 09/985,756

Filed: November 6, 2001

For: METHODS FOR THE TREATMENT OF
CELLULAR PROLIFERATIVE DISORDERS

Group Art Unit: 1635

Examiner: Unassigned

RECEIVED

MAR 15 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

1. Ikeda, K., et al., "Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses", *Nature Medicine* **5**:881-887.
2. Ikeda, K., et al., "Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant", *J. Virology* **74**:4765-4775.
3. Tyler, K.L., et al., "Molecular basis of viral apoptosis: Reovirus-induced apoptosis is associated with activation of nuclear transcription factor NfκB via the MAP kinases MEKK1 and NIK", *Neurology* **52**:A186 (abstract).

4. Thirukkumaran, C.M., et al., "Reovirus induces apoptosis in breast and prostate cell lines and activates Nf-kappa β in the nucleus: Implications for a prognostic factor in successful reovirus therapy", *Proceedings of the American Association for Cancer Research Annual* **42**:455 (abstract).

These documents are being submitted before a first Office Action on the merits, therefore no fee is required under 37 C.F.R. § 1.97(b). In the event an Office Action is mailed by the United States Patent and Trademark Office prior to receipt of this Supplemental Information Disclosure Statement, Applicants hereby make the statement specified in 37 C.F.R. §1.97(e) that each document contained herein was first cited in the International Search Report for the corresponding PCT application (PCT/CA01/01512) within 3 months of the filing date of this Supplemental Information Disclosure Statement. Therefore, no fee is required under 37 C.F.R. § 1.97(c). A copy of this International Search Report is also enclosed herewith.

For the purpose of patent term adjustment, Applicants also wish to point out that this Supplemental Information Disclosure Statement is being filed within 30 days of receipt of the aforementioned International Search Report by Applicants or Applicants' representatives.

By citing the above references, Applicants do not acquiesce or admit that any of these documents are "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

Supplemental Information Disclosure Statement

Application No. 09/985,756

Attorney's Docket No. 032775-083


Page 3

To assist the Examiner, the documents are listed on the attached form PTO-1449.
It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____


Ping F. Hwung
Registration No. 44,164
Attorney for Applicants
Redwood Shores, CA Office
(650)-622-2300

P.O. Box 1404
Alexandria, Virginia 22313-1404

Date: March 12, 2002



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**ATTORNEY'S DKT NO.
032775-083APPLICATION NO.
09/985,756APPLICANT
Matthew C. CoffeyFILING DATE
November 6, 2001GROUP
1635**U.S. PATENT DOCUMENTS**

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

RECEIVED

MAR 15 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Ikeda, K., et al., "Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses", <i>Nature Medicine</i> 5:881-887.
	Ikeda, K., et al., "Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant", <i>J. Virology</i> 74:4765-4775.
	Tyler, K.L., et al., "Molecular basis of viral apoptosis: Reovirus-induced apoptosis is associated with activation of nuclear transcription factor Nf-kappaB via the MAP kinases MEKK1 and NIK", <i>Neurology</i> 52:A186 (abstract).
	Thirukkumaran, C.M., et al., "Reovirus induces apoptosis in breast and prostate cell lines and activates Nf-kappaB in the nucleus: Implications for a prognostic factor in successful reovirus therapy", <i>Proceedings of the American Association for Cancer Research Annual</i> 42:455 (abstract).
Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.